Vitamin D deficiency is common in patients with asthma and chronic obstructive pulmonary disease (COPD). Low 25-hydroxyvitamin D (25[OH]D) levels may represent a cause or a consequence of these conditions. To determine whether vitamin D metabolism is altered in asthma or COPD. We conducted a longitudinal study in 186 adults to determine whether the 25(OH)D response to six oral doses of 3 mg vitamin D, administered over 1 year, differed between those with asthma or COPD versus control subjects. Serum concentrations of vitamin D, 25(OH)D, and 1α,25-dihydroxyvitamin D (1α,25[OH]D) were determined presupplementation and postsupplementation in 93 adults with asthma, COPD, or neither condition, and metabolite-to-parent compound molar ratios were compared between groups to estimate hydroxylase activity. Additionally, we analyzed 14 datasets to compare expression of 1α,25(OH)D-inducible gene expression signatures in clinical samples taken from adults with asthma or COPD versus control subjects. The mean postsupplementation 25(OH)D increase in participants with asthma (20.9 nmol/L) and COPD (21.5 nmol/L) was lower than in control subjects (39.8 nmol/L; = 0.001). Compared with control subjects, patients with asthma and COPD had lower molar ratios of 25(OH)D-to-vitamin D and higher molar ratios of 1α,25(OH)D-to-25(OH)D both presupplementation and postsupplementation ( ≤ 0.005). Intergroup differences in 1α,25(OH)D-inducible gene expression signatures were modest and variable if statistically significant. Attenuation of the 25(OH)D response to vitamin D supplementation in asthma and COPD associated with reduced molar ratios of 25(OH)D-to-vitamin D and increased molar ratios of 1α,25(OH)D-to-25(OH)D in serum, suggesting that vitamin D metabolism is dysregulated in these conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397796 | PMC |
http://dx.doi.org/10.1164/rccm.201909-1867OC | DOI Listing |
Int J Health Sci (Qassim)
January 2025
Department of Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People's Republic of China.
Objectives: This study aims to assess the correlation between clinical features and mortality in human immunodeficiency virus (HIV)-infected individuals with COVID-19.
Methods: A systematic literature search was conducted for cohort, cross-sectional, and case series that reported co-infection with HIV and COVID-19 published from January to September 2020. Clinical features such as age, comorbidities, CD4T lymphocyte counts, HIV RNA levels, and antiretroviral regimens were evaluated using meta-analyses and systematic reviews.
Cureus
December 2024
Chest Diseases, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, TUR.
Objectives: In this study, we aimed to demonstrate the effect of motivational interviewing with a specific cohort of smokers on smoking cessation. Furthermore, we investigated the influence of medical conditions and individual traits on the efficacy of motivational interviewing for smoking cessation.
Methods: This prospective study was conducted with smokers who presented at the pulmonology and cardiology outpatient clinic.
Front Cardiovasc Med
December 2024
Department of Cardiovascular Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, China.
Background: Cardiovascular disease(CVD) remains a significant global challenge. Asthma, which is characterized by airway hyperresponsiveness and reversible and limited airflow, plays an important role in cardiovascular diseases. This study aimed to investigate the association between asthma and CVD.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Pulmonary diseases are a major category of diseases that pose a threat to human health. The most common drugs currently used to treat lung diseases are still chemical drugs, but this may lead to drug resistance and damage to healthy organs in the body. Therefore, developing new drugs is an urgent task.
View Article and Find Full Text PDFOpen Respir Arch
November 2024
Translational Research In Airway Diseases Group (TRIAD), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Respiratory diseases and cardiovascular diseases (CVDs) have high prevalence and share common risk factors. In some respiratory diseases such as sleep apnoea and COPD, the evidence of their negative impact on the prognosis of CVDs seems clear. However, in other diseases it is less evident whether there is any direct relationship.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!